Form 4: Clover Health CEO Andrew Toy Sells Shares for Tax Obligations

Clover Health CEO Andrew Toy disposed of 85,535 Class A Common Stock shares to cover tax obligations related to RSU vesting.

Summary

• Andrew Toy, Chief Executive Officer and Director of Clover Health Investments, Corp. (CLOV), reported a disposition of Class A Common Stock.
• On November 8, 2025, 85,535 shares were disposed of at a price of $2.67 per share.
• This transaction was an automatic withholding to cover tax obligations upon the vesting of 6.25% of time-based Restricted Stock Units (RSUs).
• The original RSU grant occurred on August 8, 2022.
• Following this transaction, Andrew Toy beneficially owns 9,837,447 shares of Class A Common Stock.
• Remaining RSUs will vest quarterly in equal installments of 6.25%, with the final vesting date on August 8, 2026, contingent on continued service.

Sentiment

Score: 6

Explanation: The filing reports a routine, non-discretionary insider transaction for tax purposes upon RSU vesting. It's a neutral event, but the continued significant holding by the CEO and the pre-scheduled nature of the vesting provide a slight positive tilt by indicating stability and alignment.

Positives

• The transaction is a routine tax-related disposition, not a discretionary sale by the CEO, indicating no change in management's confidence.
• The CEO continues to hold a significant number of shares (9,837,447), demonstrating continued alignment with shareholder interests.

Negatives

• The disposition, while for tax purposes, results in a reduction of the CEO's direct shareholding.

Risks

• Future vesting of remaining RSUs is subject to the continued service of the Reporting Person on each vesting date.

Future Outlook

Remaining Restricted Stock Units (RSUs) are scheduled to vest quarterly in equal installments of 6.25%, with the final vesting occurring on August 8, 2026, contingent upon Andrew Toy's continued service to the company.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a tax-related disposition of shares upon RSU vesting. It does not provide broader insights into industry trends or competitive landscape, as it focuses solely on an individual's beneficial ownership changes.

Comparison to Industry Standards

• This filing is a standard Form 4 disclosure for an insider transaction related to RSU vesting and tax withholding. Such transactions are common across publicly traded companies when executive compensation includes equity awards.
• There are no specific comparable companies, projects, or results mentioned in this filing to assess against global benchmarks.

Stakeholder Impact

• Shareholders: The CEO's beneficial ownership remains substantial, indicating continued alignment of interests. The disposition is routine and not indicative of a loss of confidence.
• Employees: The vesting schedule and continued service requirement highlight the company's retention strategy for key executives.

Next Steps

• Remaining RSUs will vest quarterly in equal installments of 6.25%.
• The final RSU vesting date is August 8, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 details a routine, non-discretionary disposition of shares by CEO Andrew Toy to cover tax obligations upon RSU vesting. It does not reflect a change in management's outlook or a discretionary sale. The CEO retains a substantial beneficial ownership, maintaining alignment with shareholder interests. As such, this filing alone does not present new information warranting a change in investment thesis, suggesting a 'hold' recommendation.

Keywords

Clover Health, CLOV, Andrew Toy, Form 4, Insider Transaction, CEO, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership